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ABSTRACT 
Background and aims: Cannabis is one of the most commonly used substances among 
adolescents and young adults. Earlier age at cannabis initiation is linked to adverse life 
outcomes including multi-substance use and dependence. This study estimated the heritability 
of age at first cannabis use and identify associations with genetic variants.  
Methods: A twin-based heritability analysis using 8,055 twins from three cohorts was 
performed. We then carried-out a genome wide survival meta-analysis of age at first cannabis 
use in a discovery sample of 24,953 individuals from nine European, North American and 
Australian cohorts, and a replication sample of 3,735 individuals.  
Results: The twin-based heritability for age at first cannabis use was 38% (95% confidence 
interval [CI] 19-60%). Shared and unique environmental factors explained 39% (95% CI 20-
56%) and 22% (95% CI 16-29%). The genome wide survival meta-analysis identified five 
SNPs on chromosome 16 within the Calcium-transporting ATPase gene (ATP2C2) at P < 5E-
08. All five SNPs are in high LD (r2>0.8) with the strongest association at the intronic variant 
rs1574587 (P=4.09E-09). Gene-based tests of association identified the ATP2C2 gene on 
16q24.1 (P=1.33e-06). Although the five SNPs and ATP2C2 did not replicate, ATP2C2 has 
been associated with cocaine dependence in a previous study. ATP2B2, which is a member of 
the same calcium signalling pathway, has been previously associated with opioid 
dependence. SNP-based heritability for age at first cannabis use was non-significant. 
Conclusion: Age at cannabis initiation appears to be moderately heritable in Western 
countries, and individual differences in onset can be explained by separate but correlated 
genetic liabilities. The significant association between age of initiation and ATP2C2 is 
consistent with the role of calcium signalling mechanisms in substance use disorders.  
Keywords: cannabis initiation, ATP2C2, substance use, genome-wide association.   
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INTRODUCTION 
Cannabis is one of the most commonly used substances among adolescents and young adults 
(1). Annually, approximately 147 million people, or 2.5% of the world’s population, consume 
cannabis. In the last decade, cannabis use disorders have grown more rapidly than either 
cocaine or opiate use disorders, with the most rapid growth seen in developed countries in 
North America, Western Europe, and Australia (2). Accompanying these changes, there has 
also been a global trend towards decreasing age at first cannabis use (3, 4).  
Globally, younger cohorts are more likely to engage in substance use including 
cannabis. In the United States, the mean age at first cannabis use is 18 years, whereas the 
mean age at first cannabis use among individuals who initiate prior to age 21 is 16 years (1). 
European data suggest that age at first cannabis use is lower in countries where prevalence of 
cannabis use is higher (5). In addition, the male-female gap commonly observed in older 
cohorts, is closing in more recent cohorts (6, 7). Overall, these trends are likely due to lower 
risk perception (8), and increased availability due to medicalisation and decriminalisation.  
Early cannabis initiation is linked to a number of maladaptive behaviors. These 
include educational under-achievement (9, 10), possible cognitive decline (11, 12), negative 
life events (13), differences in brain maturation in at-risk adolescents (14), conduct disorder 
(15), risk-taking behaviors (16), psychosis and other psychopathology (17-20). Early age at 
onset of use is also linked to more frequent progression to cannabis misuse and increased 
likelihood of substance use disorders (21-24).  
Despite its widespread use, emerging trends in use, and associations with adverse 
outcomes, very little is known about the genetic aetiology of age at first cannabis use. A 
meta-analysis of twin studies (25) reported a heritability (h2) of ~45% for lifetime cannabis 
use (ever versus never). In contrast, only a limited number of biometric genetic studies have 
explored the heritability of age at first cannabis use. In a population-based sample of lifetime 
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users, Richmond-Rakerd et al. (26) estimated a non-significant heritability of 19% for age at 
first cannabis use. Lynskey et al. (27) reported a much larger heritability (h2=80%) for early-
onset use (≤16 years), whereas Sartor et al. (28) reported a heritability of 52% when age at 
first cannabis use was categorized as ‘never’, ‘late’ (≥17 years), or ‘early’ (≤16 years). These 
discrepancies might be due to differences in the biometrical genetic methods employed and 
the inclusion versus exclusion of never users. To address these limitations, we estimated 
heritability of age at first cannabis use using three different models to determine if cannabis 
initiation and age at initiation fall along the same continuum , represent two independent 
liabilities, or two distinct but related liabilities (29).  
We are aware of only one genome-wide association study (GWAS) for age at first 
cannabis use. Minică et al. (30) performed a genome-wide survival analysis in a sample 
comprising 5,148 participants. This study found no single nucleotide polymorphisms (SNPs) 
or genes significantly associated with age at first cannabis use, possibly due to a lack of 
statistical power (30). Because age at first use is likely to be highly polygenic (subjected to 
the influence of many genetic variants with small effects), identifying genetic variants will 
require much larger samples than previously employed. The application of survival-based 
methods (30) is expected to improve statistical power over GWASs limited to cannabis users, 
or logistic regressions based on samples of users and non-users (31-33). Therefore, we 
applied a survival-based approach to nine cohorts from the International Cannabis 
Consortium  (ICC; 34) to detect genetic variants associated with age at first cannabis use. 
The ICC was established to identify genetic variants underlying individual differences 
in cannabis use phenotypes by combining data from numerous cohorts and studies. The ICC 
has previously identified four genes significantly associated with lifetime cannabis use: 
NCAM1; CADM2; SCOC; and KCNT2 (34). Interestingly, both NCAM1 and KCNT2 have 
been previously linked to other substance use phenotypes (34). Of note is also our novel 
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finding at CADM2, which was recently associated with alcohol consumption (35), personality 
(36), behavioral reproductive outcomes and risk-taking behavior (37).  
Our aim was to explore the genetic etiology of age at first cannabis use. First, we 
performed a biometrical heritability analysis in 8,055 twins from three cohorts. Second, we 
performed a GWAS meta-analysis of age at first cannabis use in a discovery sample of 
24,953 individuals from nine cohorts from Europe, Australia, and the United States. The top 
findings were tested for replication in a sample of 3,735 individuals from three cohorts. The 
outline of the analyses steps is illustrated in Figure 1.   
 
-- Figure 1 about here -- 
 
MATERIALS AND METHODS 
 
Biometrical heritability  
The heritability of age at first cannabis use was estimated based on data from three cohorts: 
NTR comprising 2027 monozygotic (MZ) and 1771 dizygotic (DZ) twin pairs ; QIMR 
comprising 1282 MZ and 1969 DZ twin pairs ; and BLTS comprising 429 MZ and 577 DZ 
twin pairs (38). We applied three models to determine if cannabis initiation and age at 
initiation fall along the same continuum (single liability), represent two independent 
liabilities (independent model), or two distinct but related liabilities (combined model) (29). 
For the best-fitting model, individual differences in liability to early age at initation of 
cannabis use were disentangled in additive genetic (A), shared environmental (C), and 
unshared environmental variation (E) (39) (see Supplementary File S2 and Supplementary 
File S4 for details).  
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Study samples 
The current discovery meta-analysis was based on genome-wide summary statistics from 9 
European, North American, and Australian cohorts comprising N=24,953 individuals. The 
mean age ranged from 17.3 to 46.9 years (Table 1). Females represented 53.3% of the 
sample, and 44.4% of the observations were uncensored, i.e. individuals who acknowledged 
having initiated cannabis use (see Supplementary Table S1 for more details). 
 
-- Table 1 about here – 
 
Phenotyping  
Age at first cannabis use was assessed from questionnaires or clinical interviews (see 
Supplementary File S1 for information on the exact phrasing of the question). For individuals 
who had not initiated cannabis use at the time of the assessment, age at last survey or 
interview was used. Depending on initiation status, individuals were coded as uncensored 
(initiated), or censored (did not initiate at the time of the last measurement). Given the young 
average age of the participating cohorts, we included all available data to maximize sample 
size, i.e. censored and uncensored observations without imposing age restriction.  
 
Genotyping 
Genotyping followed by extensive quality control (QC) was performed by each participating 
cohort (see Supplementary Table S2 for details). Generally, QC criteria involved removal of 
SNPs with minor allele frequency (MAF) below 1%, call rates <90%, and Hardy Weinberg 
equilibrium (HWE) p-values below 1E-04. SNPs with evidence of poor clustering on visual 
inspection of intensity plots were also discarded. At the subject level, additional QC criteria 
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involved removal of individuals with low overall call rates, conflicting sex designation, or 
excess autosomal heterozygosity (indicative of genotyping errors). Duplicate samples and 
unintended 1st or 2nd degree relatives (in samples of unrelated individuals) were removed. In 
Supplementary Table S2 the exact QC thresholds used by each cohort can be found. 
 
Imputation 
All cohorts performed genotype imputation using the 1000 Genomes Phase 1 March 2012 
release as reference (40) (see Supplementary Table S2 for further imputation details). We 
used best-guess genotypes and restricted analyses to autosomal SNPs. 
 
Quality checks prior to meta-analysis 
Prior to the meta-analysis, results for each cohort underwent additional QC pertaining to 
imputation quality, minor allele frequency and HWE, and only SNPs with high imputation 
quality (>0.8) were selected. The average imputation quality for the included SNPs ranged 
from 0.95 to 0.99 across all 9 discovery cohorts. Second, we retained SNPs with MAF greater 
than √(5/N), where N is the sample size. This ensured that there were at least 5 individuals in 
the least frequent genotype group. Third, genotyped SNPs were retained if HWE was not 
violated (p-value >1E-04). We also removed SNPs with invalid alleles, or allele frequencies 
mismatched with the 1000 Genomes phase 1 European reference panel (i.e. if the allele 
frequency difference exceeded |0.2|). The discovery meta-analysis included 6,163,759 unique 
bi-allelic SNPs that passed our QC criteria in at least two cohorts (see Table 1 for the number 
of SNPs in each input file meeting quality control criteria).  
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Statistical analysis of individual samples 
Cohort-specific analyses were performed using a standardized analysis protocol. Each site 
performed a Cox proportional hazards regression analysis where age at first cannabis use (or 
age at the last survey for censored observations) was regressed on the SNP (coded additively 
co-dominant as 0, 1, 2) and the following covariates: sex, birth-cohort (to correct for 
generation effects), the first four principal components (to correct for possible population 
stratification), and study-specific covariates (to correct for chip and/or batch effects; see 
Supplementary Table 2 for details). To account for relatedness in family-based cohorts we 
used the ‘cluster’ option in the R survival package (41). This ensured that standard errors 
were robust to possible misspecification of the familial covariance matrix (42). The survival 
package was accessed either directly in R, or called from Plink (43) via the Rserve package 
(44). 
 
Meta-analysis 
The discovery meta-analysis was performed in Metal (45), using a fixed-effects model and 
the ‘SCHEME STDERR’ option, which weighs the beta coefficients by the inverse of their 
associated standard errors. To ensure that the bulk of the test statistic distribution follows the 
expectation under a theoretical null model, we applied genomic control to each cohort’s input 
file prior to meta-analysis. This ensured that none of the input cohorts contributed 
disproportionately to the meta-analysis results (46). Similar to the method applied by Furberg 
et al. (47) and Allen et al. (48), we computed the standard error (and the corresponding p-
value) by multiplying the variance of the beta by the lambdaGC (Genomic Control) estimate 
for each sample (see Supplementary Table S2). An alpha of 5E-08 was used as the genome-
wide significance threshold. Statistical analyses were performed on the Lisa Genetic Cluster 
Computer (http://www.geneticcluster.org).  
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Gene-based tests of association 
Results from the genome-wide meta-analysis were then used to test for gene-based 
association. We employed the Gene-based Association Test using the Extended Simes 
procedure (GATES) in the Knowledge-based mining system for Genome-wide Genetic 
studies (KGG) (Version 3.5) (49, 50). GATES combines the p-values of the SNPs within a 
gene by taking into account the linkage disequilibrium (LD). The SNPs were mapped onto 
(or within 5 kb) 25,655 genes based on NCBI gene coordinates. LD structure was inferred 
based on the 1000 Genomes haplotypes (version March, 2012). For this analysis, a False 
Discovery Rate (FDR) of 0.05 (51) was used as the genome-wide significance threshold. 
 
SNP-based heritability analysis 
The proportion of phenotypic variance explained by the retained SNPs was estimated using 
two different methods. The density estimation (DE) method developed by So et al. (52), 
estimates the genome-wide distribution of effect sizes based on the difference between the 
observed distribution of test statistics in the meta-analysis and the corresponding null 
distribution (for a detailed overview of the DE method, see 53). SNPs present in 25% or more 
of the meta-analysis samples were selected and pruned for LD. We used the r2=.15 pruning 
level as the primary result for consistency with other applications of this method. The second 
method used LD Score Regression analysis (54). Here, the SNP-based heritability estimate 
was based only on SNPs present in all cohorts to avoid artefacts resulting from differing Ns 
per SNP. In both methods, SNP-based heritability depends on the relationship between 
sample size, effect size, and the corresponding test statistic. Using a Cox proportional hazards 
model and applying genomic control affects that relationship. Therefore, we approximated 
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the effective sample size (i.e. the sample size with the intended statistical behavior for 
heritability analysis) of the current GWAS (for details see Supplemental File S3). 
 
Replication analyses 
Genes reaching significance and the top 8 independent signals in the discovery meta-analysis 
(present in at least one of the replication samples) were taken forward for replication in a 
sample of 3,735 individuals from three cohorts. In addition, the top SNPs were analyzed in 
the combined discovery and replication samples. Furthermore, we tested whether a polygenic 
risk score based on the meta-analysis results predicts age at first cannabis use in one of the 
replication samples (See supplementary File S5 for details on the replication analyses). We 
also evaluated the power to detect a significant association in the replication sample. 
 
RESULTS 
Biometrical Heritability 
The combined model with separate but correlated liabilities provided the best fit to the data 
(See Supplementary file S4 for model fitting details and twin correlations). In this model, the 
heritability (A) of age at first cannabis use was 38% (95% CI 19-60%). Shared (C) and 
unique (E) environmental factors explained 39% (95% CI 20-56%) and 22% (95% CI 16-
29%) of the variance, respectively. A, C, and E explained 48% (95% CI 30-65%), 37% (95% 
CI 21-52%) and 15% (95% CI 11-20%), respectively, of the variance in risk of cannabis 
initiation. We found no evidence for qualitative or quantitative sex differences. 
 
GWAS meta-analysis  
The quantile-quantile plot for the fixed effects genome-wide discovery meta-analysis is 
shown in Supplementary Figure 1a. Note that the bulk of the test statistic distribution follows 
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the expectation under a null hypothesis of no association (lambdaGC = 1). The test statistic 
behaved similarly when no genomic control was applied (see Supplementary Figure 1b). 
These results indicate that the meta-analysis is robust to slight deviations of the test statistic 
distribution from the theoretical null model observed in some of the cohorts. The 
Supplementary Figures S2a-i and S3a-i show cohort-specific lambda-corrected Manhattan 
and quantile-quantile plots. 
The Manhattan plot in Figure 2a displays the genome-wide association results. One 
region on chromosome 16 passed the significance threshold of P < 5E-08, with other 
suggestive signals on chromosomes 6, 10 and 14. Table 2 includes association results and 
details on the top 8 independent SNPs. The top 100 SNPs in the discovery sample are shown 
in Supplementary Table S3. Regional association plots and forest plots for the top SNPs are 
shown in Supplementary Figures S4a-l, Figure 1b, and Supplementary Figures S5a-k.  
 
----Figure 2 and Table 2 about here---- 
 
The genome-wide significant signals come from a set of six highly correlated SNPs 
on chromosome 16 (r2 > 0.8) located within the calcium-transporting ATPase (ATP2C2) 
gene. The strongest predictor of age at onset of cannabis use was rs1574587 (yielding the 
lowest p-value, P = 4.09E-09). rs1574587 reached statistical significance regardless of 
whether GC was applied or not (P = 1.08e-08). This SNP has a MAF ranging from 0.105 to 
0.185 across the discovery samples (commensurate with MAFs reported for European 
ancestry populations by Ensemble), and an imputation quality ≥ 0.89 (see Supplementary 
Table S4a for more details on this SNP). 
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The I2 statistic for the top SNP was 32.6% (χ2(7)=10.38, P=0.16), indicating no 
evidence of between-cohort heterogeneity in the observed effect. Indeed, the top SNP showed 
the same direction of the effect in all but one of the discovery cohorts (Figure 2b).  
 
Gene-based tests of association 
Figure 3 provides an overview of the gene-based results. The quantile-quantile plot 
(Supplementary Figure S6) shows that the bulk of the test statistic distribution follows the 
expectation under the null hypothesis and that several genomic regions are enriched for small 
p-values. Coding genic regions, and not noncoding regions, were enriched for SNPs that 
yielded strong association signals in the single variant analysis (Supplementary Figure S6). 
 
-- Figure 3 about here-- 
 
As shown in the Manhattan plot in Figure 3a, the calcium-transporting ATPase 
(ATP2C2) gene on chromosome 16 reached the FDR threshold of 0.05 in the gene-based tests 
of association (nominal P=1.33E-06, corrected P=0.034). See Supplementary Table S5 for 
the top 100 genes identified in the discovery meta-analysis and Figure 3b for the zoom plot of 
the significant gene.  
 ATP2C2 is located at 16q24.1 (Figure 3b) in the vicinity of KCNG4 and COTL1. This 
gene was also identified in the SNP-based analysis and the top SNP rs1574587 is located in 
this gene. According to the Gene Ontology annotations (56, 57) the ATP2C2 gene is involved 
in calcium-transporting ATP-ase activity, calcium ion transmembrane transport, ATP binding 
and metal ion binding.  
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SNP-based heritability analyses 
The selected SNPs did not significantly contribute to the variance in age at first cannabis use 
according to either the density estimation method (h2=0.056; P=0.29) or the LD score 
regression analysis (h2=0.036; P=0.22).   
 
Replication analyses 
The power to replicate the top 8 SNPs was low, ranging from 0.04 to 0.10 (see Supplemental 
file S5Table 2-S5). We refer to Supplemental File S5 for results of the replication analyses. 
 
 
DISCUSSION 
To our knowledge, this is the largest biometrical and molecular genetic study investigating 
the genetic etiology of age at first cannabis use. The biometrical twin analysis of 8,055 twin 
pairs showed that genetic factors explain 38% of the variance in age at first cannabis use 
(95% CI 19-60). The discovery genome-wide meta-analysis identified significant 
associations with five highly correlated SNPs within the calcium-transporting ATPase gene 
(ATP2C2) on chromosome 16. The strongest association was observed for the intronic variant 
rs1574587. The gene-based tests provided further evidence linking ATP2C2 to age at first 
cannabis use. The failure of the smaller independent replication sample to replicate the 
discovery findings was likely caused by insufficient statistical power.  
The top associated ATP2C2 gene is expressed in the brain (58) and is involved in 
calcium homeostasis (59), which in turn regulates synaptic plasticity, memory and learning 
(60). Several studies showed that variation in the ATP2C2 gene is associated with language 
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impairement (e.g. 61). ATP2C2 has also been linked to cocaine dependence. Gelernter et al. 
(62) found that the highest ranked gene networks significantly associated with cocaine 
dependence include ATP2C2 along with ATPase, Ca2+ -transporting, and the plasma 
membrane gene (ATP2B2). Noteworthy is that calcium signalling pathways have also been 
implicated in opioid dependence (63). These findings are consistent with observed 
associations between early-onset of cannabis use and experimentation with other drugs (64), 
and progression to escalated use/dependence (65). It is therefore highly plausible that some of 
the same genetic factors increase the probability of early initiation of substance use and 
progression to substance use disorders (see e.g. 66, 67). Taken together, the effects of 
ATP2C2 are likely to be general rather than substance specific.  
Early age at first cannabis use may be a predictor for more severe phenotypes such as 
substance use disorder and externalizing behaviors such as conduct disorder. Indeed, we 
know from previous work that there is high comorbidity between conduct disorder and use of 
cannabis and other substances (e.g. 68) and twin studies have shown that part of the 
covariation is due to overlapping genetic influences (69-71). It is therefore plausible that 
genes for age at first cannabis use also play a role in the broader spectrum of externalizing 
behavior. Unfortunately, existing GWASs of conduct and antisocial behavior have not been 
sufficiently powered to identify genes robustly associated with these behaviours (72, 73). 
However, using the combined effect of all SNPs, Tielbeek et al.(73) showed a significant 
genetic correlation between antisocial behavior and lifetime cannabis use (rg=0.69, p=0.016).  
The SNP-based heritability for age at first cannabis use was non-significant. 
Moreover, the polygenic risk score based on a small selection of genotyped SNPs present in 
at least 7 cohorts provided no evidence of association with age at first use of cannabis in the 
replication sample (N=2082, P>0.10). These null findings suggest that common SNPs explain 
a relatively small proportion of total heritability in age at first cannabis use. The difference 
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between the biometric ‘family-based’ and the ‘SNP-based’ heritability estimates suggests that 
a large proportion of genetic variation in age at first use of cannabis cannot be captured by 
current GWAS arrays (e.g., rare genetic variants having a MAF<0.05) at current sample 
sizes. Additional sources of discrepancy may be attributable to interactions between genetic 
loci and environmental factors (74). Detecting interaction effects also requires larger sample 
sizes and measures of environmental exposures harmonized across cohorts. 
 
Strengths and limitations 
Strengths. To our knowledge, this is the largest genome-wide study of age at first cannabis. 
This meta-analytic sample identified ATP2C2 as a risk gene, which is commensurate with the 
hypothetical role of calcium signalling mechanisms in substance use. We are unaware of any 
similarly sized meta-analysis that has fitted a survival-based method to identify genetic loci 
associated with addiction phenotypes. This approach allowed us to exploit all available 
information in the participating cohorts, while accounting for the censored nature of 
observations. Using information from both censored (i.e. individuals who reported not to 
have initiated cannabis use at the last interview) and uncensored observations for parameter 
estimation reduces the likelihood of misclassification (i.e. misclassification due to young 
participants becoming users at later ages) thereby increasing statistical power. 
Limitations. Our results should be interpreted in the context of five potential limitations. 
First, the replication sample was much smaller than the discovery sample. The size of the 
replication sample was rather modest in the context of standard GWAS of highly polygenic 
traits (75), making it difficult to distinguish false negatives from null effects. Replication 
sample sizes varied across the loci. The top genome-wide significant SNP rs1574587 met our 
quality control criteria in only one of the replication samples comprising 593 individuals. We 
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conjecture that the lack of replication was most likely due to lack of statistical power. 
Second, we imposed stringent selection criteria on the SNPs comprising the polygenic scores 
by selecting only variants present in at least 7 discovery samples and genotyped in the 
NTR2/RADAR replication sample (i.e. we removed imputed SNPs). Although this was done 
to maximize the prediction accuracy of the polygenic scores, it is possible SNPs in imperfect 
linkage disequilibrium with the causal variants were retained, as SNPs GWASs do not 
perfectly tag all causal variants, in particular,  those with low frequency and rare variants, see 
(76). Rare genetic variants have been shown to explain part of the variation in addiction 
phenotypes (77). However, sequencing of much larger samples is required to reliably locate 
rare variants. For example, we would need to include 80,000 individuals in the discovery 
sample to detect rare SNPs (MAF=0.001) with a hazard ratio of 2, and an alpha threshold of 
5E-08. Third, because our sample comprised retrospective and longitudinal cohorts, longer 
intervals between initiation and assessment may result in recall bias. However, when 
stratified by design, differences in mean age of initiation between retrospective (16.9 years) 
and longitudinal (17.1 years) studies were minor. Also, the mean age at initiation and the 
degree of censoring varied between cohorts, likely due to differences in sampling, 
assessment, drug policy, legality, and availability. To the extent to which these discrepancies 
were driven by age-related differences, the survival analyses were adjusted for the effects of 
birth cohort if variation in date of assessment spanned 20 or more years. Moreover, despite 
these differences, the top SNPs generally had an effect in the same direction across the 
samples and there was no evidence of significant between-cohort heterogeneity in the 
estimated effects (Figure 2b, Supplemental Figures S5 and Supplementary Table S3 for I2 
heterogeneity statistic). Furthermore, the forest plots indicate that the 95% confidence 
intervals surrounding the effect for each cohort mostly overlap and contain the meta-analytic 
effect. Fourth, the sample was limited to individuals of European ancestry. Whether our 
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conclusions generalize to populations of other ethnicities remains subject to further 
investigation. Fifth, we did not collect information on cannabis use opportunities. Recent 
findings suggest that drug use opportunity should be taken into account when investigating 
genetic influences on drug use as high genetic risk for drug use may not lead to initiation of 
use when there is a lack of opportunity to do so.    
 
Conclusion 
To date, this study is the largest GWAS meta-analysis of age at first cannabis use. Our SNP-
based findings support the involvement of the ATP2C2 gene. The gene-based tests also 
identified the ATP2C2 gene as a significant predictor of age at onset. Our findings are 
commensurate with the role of calcium signalling mechanisms in substance use disorders. 
The failure to replicate is likely attributable to lack of statistical power. Further investigation 
of these signals in larger samples is warranted and may yield valuable insights into the 
genetic etiology of substance use initiation. 
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Figure legends: 
 
Figure 1: The outline of the analysis steps, and references to the Supplementary Material 
relevant to each step. Abbreviations: AFC – age at first cannabis use; DE – density 
estimation; LDSR – linkage disequilibrium score regression. 
 
Figure 2: The Manhattan plot of the meta-analysis results for the discovery sample (a). In the 
Manhattan plot, the y-axis shows the strength of association (-log10(P)) and the x-axis 
indicates the chromosomal position. The blue line indicates suggestive significance level (P < 
1E-05) while the red line indicates genome-wide significance level (P < 5E-08); (b) Forest 
plot of the top SNP (rs1574587) on Chromosome 16 in eight discovery cohorts.  
 
Figure 3: Results of the gene-based tests: (a) Manhattan plot for the gene-based tests; and (b) 
Regional plot around the significantly associated gene 
